Memantine Effects on Sensorimotor Gating and Neurocognition in Schizophrenia

a study on Schizophrenia Psychotic Disorders Schizoaffective Disorder

Summary

Eligibility
for people ages 18-50 (full criteria)
Healthy Volunteers
healthy people welcome
Location
at San Diego, California
Dates
study started
estimated completion
Principal Investigator
by Neal R. Swerdlow, M.D., Ph.D.
Photo of Neal R. Swerdlow
Neal R. Swerdlow

Description

Summary

This application seeks to determine if neurophysiological metrics of memantine (MEM)-enhanced early auditory information processing (EAIP) in schizophrenia (SZ) mediate gains in auditory processing fidelity (APF) and auditory learning.

Keywords

Schizophrenia Schizo Affective Disorder Schizoaffective Disorder Healthy Disease Psychotic Disorders Mood Disorders Memantine

Eligibility

You can join if…

Open to people ages 18-50

  • diagnosis of schizophrenia OR schizoaffective-depressed OR healthy subjects
  • ages 18-50 for all subjects
  • double barrier contraception for all subjects
  • not pregnant for all subjects

You CAN'T join if...

  • DSM-IV Axis I or II Diagnosis for for healthy subjects
  • MEM or amantadine for patients
  • current substance abuse for all subjects
  • current recreational drug use for all subjects
  • history of other significant medical illness (e.g. cancer, diabetes, heart disease, HIV, seizures) for all subjects
  • open head injury or closed head injury with loss of consciousness > 1 min for all subjects
  • hearing or visual impairment for all subjects
  • pregnancy for all subjects
  • dementia for all subjects
  • mental retardation for all subjects

Location

  • Clinical Teaching Facility (CTF-B102) at UCSD Medical Center accepting new patients
    San Diego California 92103 United States

Lead Scientist at UCSD

  • Neal R. Swerdlow, M.D., Ph.D.
    Biography Neal Swerdlow, M.D., Ph.D. is Professor of Psychiatry, Director of the Research Residency Track and Vice Chair of Education and Training in the Department of Psychiatry at the University of California, San Diego, School of Medicine. Dr. Swerdlow graduated Summa Cum Laude, Phi Beta Kappa, from Amherst College (Neuroscience) in 1981, received his M.D. and Ph.D.

Details

Status
accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
University of California, San Diego
ID
NCT03860597
Phase
Phase 4
Study Type
Interventional
Last Updated
Contact us about this trial